Ignite Creation Date:
2024-05-05 @ 11:41 AM
Last Modification Date:
2024-10-26 @ 9:11 AM
Study NCT ID:
NCT00105092
Status:
COMPLETED
Last Update Posted:
2007-05-01
First Post:
2005-03-04
Brief Title:
Enzastaurin as Second and Third-Line Treatment for Non-Small Cell Lung Cancer
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Organization Data
Organization:
Eli Lilly and Company
Class:
INDUSTRY
Study ID:
8670
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Eli Lilly and Company
Lead Sponsor Class:
INDUSTRY
Responsible Party:
None
Responsible Party Title:
None
Responsible Party Type:
None
Responsible Party Affiliation:
None
Old Name:
None
Old Organization:
None